Immunotherapy in thymic epithelial tumors: an attractive dilemma [0.03%]
免疫治疗在胸腺上皮肿瘤中的应用：一个充满诱惑的两难困境
Nahed Damaj,Dany Nassar,Bilal Chamaa et al.
Nahed Damaj et al.
Thymomas and thymic carcinomas are the most prevalent tumors that develop in the thymus's epithelial tissue. Thymomas are malignant tumors that develop from the epithelial cells of the thymus and frequently include mixed populations of lymp...
A Phase 1b study of the OxPhos inhibitor ME-344 with bevacizumab in refractory metastatic colorectal cancer [0.03%]
线粒体氧化磷酸化抑制剂ME-344与贝伐单抗治疗难治性转移性结直肠癌Ib期临床研究
Patrick M Boland,Heinz-Josef Lenz,Kristen K Ciombor et al.
Patrick M Boland et al.
Antiangiogenic drugs may cause vascular normalization and correct hypoxia in tumors, shifting cells to mitochondrial respiration as the primary source of energy. In turn, the addition of an inhibitor of mitochondrial respiration to antiangi...
Deficiency of myeloid discoidin domain receptor 2 aggravates melanoma lung and bone metastasis [0.03%]
髓系盘状结构域受体2缺乏加重黑色素瘤肺和骨转移
Yue Sun,Liangliang Wei,Hao Liu et al.
Yue Sun et al.
Melanoma, one of the most prevalent cancers worldwide, frequently metastasizes to the lung and bones. Tumor-associated macrophages play essential roles in melanoma metastasis but the underlying mechanism remains obscure. We previously demon...
Clinical features, treatment, and outcomes of nivolumab induced psoriasis [0.03%]
纳武单抗诱导的银屑病的临床特征、治疗及转归
Shaoli Zhao,Wei Sun,Jichun Sun et al.
Shaoli Zhao et al.
Psoriasis is an uncommon immune-mediated adverse event linked to nivolumab, and its clinical characteristics remain inadequately defined. This study aims to investigate the clinical features and patterns of nivolumab-induced psoriasis, prov...
5-Fluorouracil-methotrexate conjugate enhances the efficacy of 5-fluorouracil in colorectal cancer therapy [0.03%]
5-氟尿嘧啶-甲氨蝶呤缀合物可增强其在结直肠癌治疗中的疗效
Siyuan Zhao,Tiansi Wang,Kourong Shi et al.
Siyuan Zhao et al.
To extend the short half-life of fluorouracil (Fu), enhance its tumor targeting, improve efficacy, and reduce side effects, providing a new approach for colorectal cancer treatment. Fluorouracil was hydroxylated and conjugated with methotre...
Efficacy and safety of the combination of envafolimab and lenvatinib in unresectable hepatocellular carcinoma: a single-arm, multicentre, exploratory phase II clinical study [0.03%]
恩维纳利玛联合仑伐替尼治疗不可切除的肝细胞癌的疗效和安全性：一项单臂、多中心探索性Ⅱ期临床研究
Yi Jiang,Ke Su,Han Li et al.
Yi Jiang et al.
Currently, therapeutic combinations of immune checkpoint inhibitors (ICIs) with anti-angiogenic agents have shown promising outcomes and have the potential to establish a new standard of care. The efficacy and safety of the first-line combi...
Nan Chen,Qin Zhang,Lei Sun et al.
Nan Chen et al.
Sarcomas, including bone sarcomas and soft tissue sarcomas (STSs), are a heterogeneous group of mesenchymal malignancies. Recent advancements in next-generation sequencing (NGS) have enabled the identification of novel chromosomal transloca...
Vebreltinib: a promising milestone in targeted therapy for METex14-mutant NSCLC [0.03%]
维伯替尼在MET外显子14跳变非小细胞肺癌靶向治疗中的前景与展望
LinRui Ma,WeiKang Meng,WenJuan Jiang
LinRui Ma
Efficacy of immune checkpoint inhibitor rechallenge in initial immunotherapy responders with advanced non-small cell lung cancer: A single-center retrospective study [0.03%]
免疫检查点抑制剂治疗后复发的晚期非小细胞肺癌既往治疗获益患者的再挑战疗效研究：一项单中心回顾性研究
Manyi Xu,Yanhua Wang,Ke Wang et al.
Manyi Xu et al.
Background: The efficacy of immune rechallenge in patients with advanced non-small cell lung cancer (NSCLC) who responded well to initial immune checkpoint inhibitor (ICI) treatment is becoming a research hotspot. This st...
Neoadjuvant immunochemotherapy in locally advanced laryngeal cancer and hypopharyngeal cancer: higher objective response rate and organ-preservation rate [0.03%]
局部晚期喉癌和下咽癌新辅助免疫化疗：更高的客观缓解率和器官保护率
Shaoshi Chen,Qi Zhong,Shurong Zhang et al.
Shaoshi Chen et al.
This study retrospectively analyzed the curative effect of neoadjuvant PD-1 inhibitors combined with chemotherapy of locally advanced laryngeal and hypopharyngeal cancer and compared with chemotherapy plus EGFR inhibitors and chemotherapy a...